Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-NODAGA-SNA014 PET/CT for Gastric, GEJ, and Pancreatic Cancer
NCT06646783Phase 1Not yet recruiting
- Sponsor
- SmartNuclide
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]Ga-NODAGA-SNA014 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and pancreatic cancer (PC), sponsored by SmartNuclide. Primary endpoints: Biological distribution characteristics at 1 week and Safety tolerance characteristics at 1 year. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
[68Ga]Ga-NODAGA-SNA014
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06646783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646783.